Function of CK2 kinase activity in Th17 cell polarization and EAE (BA4P.125)

Sara Gibson,Hongwei Qin,Yudong Liu,Amber Buel,Etty Benveniste

DOI: https://doi.org/10.4049/jimmunol.194.supp.47.5

2015-05-01

The Journal of Immunology

Abstract:Abstract Auto-reactive CD4+ T cells drive many autoimmune diseases including multiple sclerosis and colitis. Th1 and Th17 cells are pathogenic in the context of autoimmunity while Treg cells promote disease resolution. CK2 is a constitutively expressed and highly conserved serine/threonine kinase that promotes a number of pro-survival and pro-inflammatory signaling pathways including PI3K/Akt/mTOR, NF-κB, and JAK/STAT. These pathways are essential for CD4+ T cell activation and polarization, but little is known about how CK2 functions in T cells. Here we demonstrate that protein levels of the major catalytic subunit of CK2, CK2α, and CK2 kinase activity are elevated in murine CD4+ T cells polarized to the Th1 and Th17 phenotypes in vitro compared to naïve CD4+ T cells. Furthermore, CK2α expression is elevated in CD4+ T cells that are activated and infiltrate the central nervous system during EAE, a murine model of MS. Using the small molecule inhibitor CX-4945, which targets CK2α, we demonstrate that CK2 kinase activity promotes Th17 cell polarization in vitro, but not the polarization of Th1 or Treg cells. Additionally, in vivo treatment with CX-4945 during EAE resulted in a dampened MOG-specific Th17 response and a decrease in IL-17A+ and IL-17A+IFN-γ+ CD4+ T cells present in the central nervous system. Our data implicate CK2 as a novel regulator of T cell differentiation, and suggest that CK2 could be targeted in Th17 cell driven autoimmune disorders.

immunology